CTOs on the Move

TAU Systems

www.tausystems.com

 
TAU Systems is a deep-tech company developing the first compact particle accelerators and specialized X-ray free-electron lasers that combine the capabilities of large accelerators with a small footprint to provide easy and affordable beam-time access for any company. Led by premier experts in laser-driven particle accelerators, TAU is democratizing access for the progress of biotechnology, nuclear and more.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tausystems.com
  • 201 West 5th Street Suite 1100
    Austin, TX USA 78701
  • Phone: 512.900.1230

Executives

Name Title Contact Details
Nikolaus Metzger
Director of Laser Science and Technology Profile

Similar Companies

American Type Culture Collection

ATCC, the premier global biological materials resource and standards organization serves and supports the scientific community with industry-standard products and innovative solutions. With the world’s largest and most diverse collection of human and animal cell lines, microorganisms, nucleic acids, molecular genomic tools, and biological products, ATCC is a trusted resource for the worldwide research community. Together, the people of ATCC share in its mission to acquire, authenticate, preserve, develop, and distribute biological materials and information for the advancement of scientific knowledge.

Ash Stevens Inc

Founded in 1962, Ash Stevens is a premier contract research organization that provides low-volume, high-value Active Pharmaceutical Ingredients (APIs). We understand the industry needs and utilize our expertise in pharmaceutical regulatory affairs to

PNP Therapeutics

PNP Therapeutics is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alvine Pharmaceuticals

Alvine Pharmaceuticals is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tscan

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.